share_log

Altamira Therapeutics | CORRESP: CORRESP

Altamira Therapeutics | CORRESP: CORRESP

Altamira Therapeutics | CORRESP:信函
美股SEC公告 ·  04/16 12:50

Moomoo AI 已提取核心信息

Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-1 effective by 4:00 p.m. Eastern Time on April 17, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. The company's CEO, Thomas Meyer, signed the request, which was facilitated by Alex Dinur of Lowenstein Sandler LLP. Altamira Therapeutics is awaiting confirmation from the SEC for the effectiveness of their Registration Statement, which is a critical step in the process of a public offering.
Altamira Therapeutics Ltd.已正式要求美国证券交易委员会(SEC)宣布其F-1表格的注册声明在东部时间2024年4月17日下午4点之前生效。该请求是根据1933年《证券法》第461条提出的,是通过EDGAR提交的信函提交的。该公司首席执行官托马斯·迈耶签署了该请求,洛文斯坦·桑德勒律师事务所的亚历克斯·迪努尔为该请求提供了便利。Altamira Therapeutics正在等待美国证券交易委员会确认其注册声明的有效性,这是公开募股过程中的关键一步。
Altamira Therapeutics Ltd.已正式要求美国证券交易委员会(SEC)宣布其F-1表格的注册声明在东部时间2024年4月17日下午4点之前生效。该请求是根据1933年《证券法》第461条提出的,是通过EDGAR提交的信函提交的。该公司首席执行官托马斯·迈耶签署了该请求,洛文斯坦·桑德勒律师事务所的亚历克斯·迪努尔为该请求提供了便利。Altamira Therapeutics正在等待美国证券交易委员会确认其注册声明的有效性,这是公开募股过程中的关键一步。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息